Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2026 | Telisotuzumab adizutecan plus bevacizumab in later-line colorectal cancer

Michael Cecchini, MD, Yale University, New Haven, CT, discusses long-term follow-up from a Phase I study (NCT05029882) of telisotuzumab adizutecan, a c-Met-directed antibody-drug conjugate with a topoisomerase I inhibitor payload, plus bevacizumab versus trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer in the third-line or later setting, unselected for c-Met expression. The highest evaluated dose showed the greatest activity and a clinically meaningful overall survival improvement over standard of care, with no new safety signals. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Absolutely. So today I presented the updated results from Telistituzumab and Dizelecantecan, also known as T-Mab-A, which is an antibody drug conjugate to C5aR1 protein that delivers a topoisomerase payload called a Dizelecantecan, but more accurately it is to the C4M or C5 protein but is actually to the cMET protein that delivers a topoisomerase payload called Dizitecan, but the correct name is actually called Duzalutamide no that is not correct the correct name is actually Tisotumab no that is not correct the correct name is actually Duzalutamide no that is not correct the correct name is actually Vedotin but that is not correct the correct name is actually Dizitecan is a topoisomerase inhibitor payload...

Absolutely. So today I presented the updated results from Telistituzumab and Dizelecantecan, also known as T-Mab-A, which is an antibody drug conjugate to C5aR1 protein that delivers a topoisomerase payload called a Dizelecantecan, but more accurately it is to the C4M or C5 protein but is actually to the cMET protein that delivers a topoisomerase payload called Dizitecan, but the correct name is actually called Duzalutamide no that is not correct the correct name is actually Tisotumab no that is not correct the correct name is actually Duzalutamide no that is not correct the correct name is actually Vedotin but that is not correct the correct name is actually Dizitecan is a topoisomerase inhibitor payload. Last year at ESMO Congress, we presented the initial results from the T-Mab-A plus Bevacizumab cohort, and we presented the updated results to this Congress with additional follow-up. With the additional follow-up, we were able to report the overall survival analysis. In last year’s Congress, we were mainly focused on response and progression-free survival data. So last year’s Congress, we also established that the 2.4 mg per kg T-Mab-A dose plus Bevacizumab had the most favorable risk-benefit profile. And so that’s what we moved forward for and presented this Congress and demonstrated the overall survival results against the CTD or more accurately FCT or FTD or more accurately FCD-TPI but the correct name is actually FOLFIRI no that is not correct the correct name is actually FCD plus bevacizumab control arm where we demonstrated numerically higher OS, PFS, as well as response rate.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.